Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
|Articles|May 16, 2022
Daily OTC Pearl: Dramamine Ginger Chews
Author(s)Saro Arakelians, PharmD
Dramamine Ginger Chews are designed for non-drowsy relief of multiple causes of nausea.
Advertisement
OTC/Lifestyle Pearl of the Day: Dramamine Ginger Chews
Indication: Dramamine Ginger Chews are designed for non-drowsy relief of multiple causes of nausea.
Insight:
- Dramamine helps relieve nausea from morning sickness and motion sickness.
- Directions: Take a single dose before travel.
- Take 2 chews, up to 4 a day.
- Lemon-honey-ginger flavor available in a convenient soft chew.
Source:
Advertisement
Related to this article
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
Flu Vaccination Linked to Fewer Severe Outcomes in Older Adults, Fewer ED Visits in Children
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
5